Abstract
Objective: The ORIENT-32 clinical trial revealed that sintilimab plus bevacizumab biosimilar significantly improved the median progression-free survival and median overall survival (OS) compared with sorafenib. This analysis evaluated the cost-effectiveness of sintilimab plus bevacizumab biosimilar as a first-line treatment for unresectable hepatocellular carcinoma from the Chinese perspective of healthcare system. Materials and methods: A Markov model with three mutual health states was constructed to evaluate the economic outcome of sintilimab plus bevacizumab biosimilar. The model cycle was 21 days, and the simulation time horizon was a lifetime. The output parameters of the model were the total cost, life-year (LY), quality-adjusted LY (QALY), and incremental cost-effectiveness ratio (ICER). Sensitivity analyses were conducted to assess the robustness of the results. Results: The base-case results found that sintilimab plus bevacizumab biosimilar provided an improvement of 1.27 QALYs and 1.84 LYs compared with sorafenib, and the ICER was $23,352/QALY. The hazard ratio for OS had the greatest influence on the ICER. The probability of sintilimab plus bevacizumab biosimilar was 85% at willingness-to-pay thresholds of $30,552/QALY. Conclusion: The findings of this analysis suggested that sintilimab plus bevacizumab biosimilar was a cost-effective first-line therapy for patients with unresectable hepatocellular carcinoma.
Highlights
Primary liver cancer is the third leading cause of cancer-related deaths in the world, with an estimated 830,000 deaths in 2020 (Sung et al, 2021)
The base-case results found that sintilimab plus bevacizumab biosimilar provided an improvement of 1.27 qualityadjusted LY (QALY) and 1.84 LYs compared with sorafenib, and the incremental cost-effectiveness ratio (ICER) was $23,352/QALY
The probability of sintilimab plus bevacizumab biosimilar was 85% at willingness-topay thresholds of $30,552/QALY. The findings of this analysis suggested that sintilimab plus bevacizumab biosimilar was a cost-effective first-line therapy for patients with unresectable hepatocellular carcinoma
Summary
Primary liver cancer is the third leading cause of cancer-related deaths in the world, with an estimated 830,000 deaths in 2020 (Sung et al, 2021). The predominant causative factor of HCC is hepatitis B virus (HBV). Recent research progress has shown that the combination of anti–programmed cell death-1 (PD-1) antibodies and antiangiogenic drugs may become a potential first-line therapy for HCC (Ren et al, 2021). The ORIENT-32 clinical trial evaluated the efficacy and safety of sintilimab, a selective anti-PD-1 antibody (Gao et al, 2020), in combination with bevacizumab biosimilar in the treatment of unresectable HCC (Ren et al, 2021). The sintilimab plus bevacizumab biosimilar therapy seems to be an attractive option as a firstline treatment for unresectable HCC. The present analysis evaluated the cost-effectiveness of sintilimab plus bevacizumab biosimilar as a first-line treatment for unresectable HCC from the perspective of the Chinese healthcare system
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
